PTH and Hepatitis: Between 2011 and 2014, 94 consecutive RA patients were invited to participate in the study; a total of 34 were excluded from the study as follows: premenopausal state at age > 45 (n = 13), malignoma (n = 5), ongoing hormone replacement therapy (n = 6), inadequate RA diagnosis (n = 2), insufficient scan quality (n = 2), thyroid disorders (n = 3), hepatitis (n = 1), neuropathy (n = 1) or osteoanabolic therapy with PTH (n = 1).